fate therapeutics stock price target

Fate Therapeutics Inc. The firm presently has a buy rating on the biopharmaceutical companys stock.

Fate Therapeutics Fate Stock Price News Info The Motley Fool

Barclays Increases EOG Resources NYSEEOG Price Target to 14300.

. Fate Therapeutics stock forecasts are adjusted once a day based on the closing price of the previous trading day. Ad 1000 Strong Buy Stocks that Double the SP. 2 days agoHC Wainwright cut their target price on shares of Fate Therapeutics from 12200 to 11500 and set a buy rating for the company in a research note on Friday March 4th.

Finally HC Wainwright cut their target price on shares of Fate Therapeutics from 12200 to 11500 and set a buy rating for the company in. Fate Therapeutics NASDAQFATE Get Rating had its target price cut by analysts at HC Wainwright from 12200 to 11500 in a research note issued to investors on Friday Benzinga reports. The 18 analysts offering 12-month price forecasts for Fate Therapeutics Inc have a median target of 9900 with a high estimate of 13500 and a.

Morgan Stanley lowered their price target on shares of Fate Therapeutics from 7400 to 6200 and set an equal weight rating for the company in a research report on Wednesday December 15th. 5 Wall Street analysts that have issued a 1 year FATE price target the average FATE price target is 9360 with the highest FATE stock price forecast at 11500 and the lowest FATE stock price forecast at 7400. Learn more on FATEs analyst rating history.

The minimum target price for Fate Therapeutics analysts is 9453. New Look At Your Financial Strategy. FATE stock quote history news and other vital information to help you with your stock trading and investing.

NASDAQFATE traded at 3244 at close of the session on Tuesday 042622 made a downward move of -849 on its previous days price. 50 Day Moving Average is the support level 3662. HC Wainwright Adjusts Fate Therapeutics Price Target to 115 from 122 Keeps Buy Rati.

According to analysts consensus price target of 9300 Fate Therapeutics has a forecasted upside of 1595 from its current price of 3584. In terms of how Fate Therapeutics Inc fares relative to Pharmaceutical Products stocks note that its average analyst price target is higher than 145991 of that group. Chart FATE THERAPEUTICS INC.

Looking at the stock we see that its previous close was 3545 and the beta 5Y monthly reads 156 with the days price range being 3243 3581. The average twelve-month price target for Fate Therapeutics is 9300 with a high price target of 14500 and a low price target of 6000. 7 2020 at 718 am.

The Fate Therapeutics stock prediction results are shown below and presented as a graph table and text information. 69 rows FATE Stock Trend. The stock is moving within a very wide and.

Nasdaq AT CLOSE 400 PM EDT 041222. A number of equities analysts have recently issued reports on the stock. The average 12 month price target among brokers that have issued ratings on the stock in the last year is 8722.

Fate Therapeutics stock forecasts are adjusted once a day based on the closing price of the previous trading day. The minimum target price for Fate Therapeutics analysts is 9489. Visit The Official Edward Jones Site.

Find the latest Fate Therapeutics Inc. ET by Tomi Kilgore Fate Therapeutics stock price target raised to 65 from 40 at Truist. Fate Therapeutics NASDAQFATE Price Target Lowered to 7500 at Truist Financial.

Ad Do Your Investments Align with Your Goals. According to the issued ratings of 10 analysts in the last year the consensus rating for Fate Therapeutics stock is Buy based on the current 2 hold ratings and 8 buy ratings for FATE. Find a Dedicated Financial Advisor Now.

Today 200 Day Moving Average is the resistance level 5926. AFTER HOURS 543 PM EDT 041222. Amount of Analyst Coverage Fate Therapeutics has only been the subject of 3 research reports in the past 90 days.

2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max. FATE has a greater upside potential average analyst target price relative to current price than 149379 of stocks in the mid market cap category. Fate Therapeutics stock price target raised to 88 from 55 at Wedbush Dec.

Wedbush Adjusts Fate Therapeutics Price Target to 77 From 74 Keeps Outperform Ratin.

Fate Fate Therapeutics Inc Stock Overview U S Nasdaq Barron S